WO2014055895A1 - Dispositif injectable et méthode de modelage, d'augmentation ou de correction de traits faciaux tels que du menton - Google Patents

Dispositif injectable et méthode de modelage, d'augmentation ou de correction de traits faciaux tels que du menton Download PDF

Info

Publication number
WO2014055895A1
WO2014055895A1 PCT/US2013/063507 US2013063507W WO2014055895A1 WO 2014055895 A1 WO2014055895 A1 WO 2014055895A1 US 2013063507 W US2013063507 W US 2013063507W WO 2014055895 A1 WO2014055895 A1 WO 2014055895A1
Authority
WO
WIPO (PCT)
Prior art keywords
peg
composition
hyaluronic acid
mosm
gmf
Prior art date
Application number
PCT/US2013/063507
Other languages
English (en)
Inventor
Dimitrios Stroumpoulis
Ahmet Tezel
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of WO2014055895A1 publication Critical patent/WO2014055895A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

  • the present invention generally relates to implantable prosthesis and more specifically relates to an injectable device for adding structure and contour to the lower face.
  • Dermal fillers are sometimes used by cosmetic and reconstructive surgeons as a way to add more volume to the face, rather than to simply correct wrinkles and folds.
  • Hyaluronic acid is still considered the most desirable dermal filler in that it does not pose the risk of an allergic reaction and it is temporary.
  • the great majority of hyaluronic acid -based dermal fillers were developed specifically for treating wrinkles and folds in skin, not for facial contouring.
  • HA-based fillers are limited for this indication because the dermal filler formulations lack adequate ability to lift while providing long-lasting results in this anatomic area.
  • an injectable hyaluronic acid based dermal filler that is specifically designed to be effective in adding substantial volume to the face, for example, for contouring the lower face, for example, for augmenting or correcting the chin, for example, for correction of chin retrusion.
  • the shape of the chin has long been recognized as an important feature of the face that elicits a strong aesthetic perception that tends to be associated with personality traits of an individual.
  • a deficient chin that lacks projection is commonly labeled a "weak chin" while prominent chins are labeled "strong chins”, both implying strength of personality.
  • Chin augmentation is generally performed not through the use of dermal fillers designed for treating wrinkles and fold lines in the skin, but by surgically placing a permanent implant above the jaw.
  • the procedure is currently among the top aesthetic surgical procedures performed, based on the American Society for Aesthetic Plastic Surgery (ASAPS), and has increased 71% from 2010.
  • ASAPS American Society for Aesthetic Plastic Surgery
  • an injectable device for facial sculpturing, for example, for augmenting or correcting the chin in a human being.
  • the device generally comprises a composition comprising a hyaluronic acid (HA), preferably a low molecular weight HA, crosslinked with a non-BDDE, multifunctional crosslinking agent, for example, a multifunctional polyethylene glycol (PEG)-based crosslinking agent, the composition being suitable for injection and capable of augmenting and providing substantial volume, lift and/or sculpturing of the lower face, for example, the chin.
  • HA hyaluronic acid
  • PEG polyethylene glycol
  • the multifunctional PEG-based crosslinking agent may be a bifunctional PEG-based crosslinking agent, a trifunctional PEG-based crosslinking agent, a tetrafunctional PEG-based crosslinking agent, a pentafunctional PEG-based crosslinking agent, a hexafunctional PEG- based crosslinking agent, a heptafunctional PEG-based crosslinking agent, an octafunctional PEG-based crosslinking agent, a nonafunctional PEG-based crosslinking agent, or a decafunctional PEG-based crosslinking agent.
  • the crosslinking agent is a tetrafunctional polyethylene glycol (PEG)-crosslinking agent.
  • the tetrafunctional crosslinker is pentaerythritol tetraglycidyl ester.
  • the hyaluronic acid, prior to crosslinking is substantially entirely, or 100%, low molecular weight hyaluronic acid, for example, a HA having a mean molecular weight of between about 300,000 Da and about 840,000 Da.
  • the composition has an HA concentration of between about 20 mg/g and about 30 mg/g, for example, an HA concentration of about 22 mg/g, for example, about 23 mg/g, for example, about 24 mg/g, for example, about 25 mg/g, for example, about 26 mg/g, for example, about 27 mg/g, for example, about 28 mg/g, for example, about 29 mg/g, for example, about 30 mg/g.
  • the composition has an HA concentration of between 22.5 mg/g to 27.5 mg/g, for example, 25.0 mg/g, or for example 23.5 mg/g.
  • the composition comprises a multifunctional PEG- crosslinked hyaluronic acid, the composition including between about 5% and about 25% crosslinking agent/NaHA w/w, for example, between about 10% and about 20% of the crosslinking agent, for example, about 12%, about 13%, or about 15% crosslinking agent/NaHA, and the crosslinking agent is, for example, pentaerythritol tetra glycidyl ether.
  • the compositions comprises low molecular weight hyaluronic acid (NaHA) crosslinked with about 13% of pentaerythritol tetra glycidyl ether (PEGE)/NaHA (w/w), and formulated to a concentration of about 25 mg/g with 0.3% lidocaine hydrochloride (w/w) in a phosphate buffer.
  • NaHA low molecular weight hyaluronic acid
  • PEGE pentaerythritol tetra glycidyl ether
  • lidocaine hydrochloride w/w
  • methods are provide for contouring or correcting a facial feature of an individual, the methods comprising the step of subdermally administering into the facial feature of the patient, an effective amount, for example, about 1.0 ml, or more, for example, about 2.0 ml or more, for example, about 3.0 ml or more, of a composition of the invention.
  • the facial feature may be a chin, for example, a retruded chin of a patient.
  • methods for correcting a retruded chin of a patient, the method comprising supraperiostally administering in the chin of the patient, an effective amount of a composition comprising a low molecular weight hyaluronic acid crosslinked with a PEG-based, non-BDDE crosslinker, for example, a pentaerythritol tetraglycidyl ester crosslinker.
  • a composition comprising a low molecular weight hyaluronic acid crosslinked with a PEG-based, non-BDDE crosslinker, for example, a pentaerythritol tetraglycidyl ester crosslinker.
  • PEG-based crosslinking agent is synonymous with “PEG-based crosslinker” and refers to a PEG molecule comprising at least two reactive sites useful to covalently conjugate another molecule to the PEG molecule.
  • PEG comprises a group of biocompatible, hydrophilic, and inert polymers having the general formula HO(CH 2 CH 2 0) n H, where n is an integer from 2 to 100, which is synthesized by the polymerization of ethylene oxide.
  • a PEG molecule can be linear or branched.
  • Branched PEGs include, without limitation, forked PEGs, star PEGs, comb PEGs, brush PEGs, and graft PEGs.
  • a forked PEG is a branched PEG comprising two polymer chains emanating from a single branch point.
  • a star PEG is a branched PEG comprising three or more linear polymer chains emanating from a central core group or a single branch point.
  • a comb PEG is a branched PEG comprising two or more three-way branch points and linear side chains emanating from a main backbone polymer chain.
  • a brush PEG is a branched PEG comprising three or more linear polymer chains emanating from a main backbone polymer chain.
  • a graft PEG is a branched PEG comprising two or more polymer chains where one or more polymer chains are different, structurally or configurationally, from the main chain.
  • the polymer chains comprising a PEG may be blocked.
  • a branched PEG can be referred to by the number of polymer chains is comprises.
  • a branched PEG having three polymer chains is referred to as a three-arm PEG or 3 -arm PEG
  • a branched PEG having four polymer chains is referred to as a four-arm PEG or 4-arm PEG
  • a branched PEG having five polymer chains is referred to as a five-arm PEG or 5 -arm PEG
  • a branched PEG having six polymer chains is referred to as a six- arm PEG or 6-arm PEG
  • a branched PEG having seven polymer chains is referred to as a seven- arm PEG or 7-arm PEG, etc.
  • PEG poly(ethylene glycol)
  • the physical properties of PEG can be altered by varying the length of the polymer chain, the type of initiator used during the polymerization process, and/or whether the PEG has a linear or branched configuration.
  • PEG molecules both linear and branched, are commercially available over a wide range of molecular weights from 300 g/mol to 10,000,000 g/mol.
  • a polymer chain of a PEG-based crosslinking agent may be functional in that it comprises a reactive site used to conjugate the PEG chain to another molecule.
  • a PEG-based crosslinker containing more than one reactive site is referred to generally as a multifunctional PEG-based crosslinker, or more specifically by the number of reactive sites it contains.
  • a bifunctional PEG-based crosslinker has two reactive sites useful for crosslinking purposes
  • a trifunctional PEG-based crosslinker has three reactive sites useful for crosslinking purposes
  • a tetrafunctional PEG-based crosslinker has four reactive sites useful for crosslinking purposes
  • a pentafunctional PEG-based crosslinker has five reactive sites useful for crosslinking purposes
  • a hexafunctional PEG-based crosslinker has six reactive sites useful for crosslinking purposes
  • a heptafunctional PEG-based crosslinker has seven reactive sites useful for crosslinking purposes, etc.
  • the number of functional sites on a PEG-based crosslinker disclosed herein is limited only by the ability of the hyaluronic acid polymer strands to bind to the resulting active sites on the crosslinker due to, e.g., geometry and steric hindrance.
  • a polymer chain of a PEG-based crosslinking agent is made functional by attaching a reactive group to the free end of a polymer chain from a base PEG molecule.
  • Any reactive group that can be used to covalently join glycosaminoglycan polymers to the PEG-based crosslinker may be used, including, without limitation, epoxides.
  • the PEG-based crosslinking agents disclosed herein may be made according to any PEG synthesis methods known to one of ordinary skill in the art. Generally, a multifunctional PEG-based crosslinking agent is synthesized from a base poly-alcohol or PEG molecule having the desired chain length and branching by attaching epoxide groups.
  • Such epoxide groups can be attached to the base poly- alcohol or PEG molecule by deprotonating the hydroxyl groups and reacting with epichlorohydrin.
  • Example 1 describes the synthesis of a specific PEG-based crosslinking agent disclosed herein.
  • a PEG-based crosslinker may have a variety of polymer chain lengths which affect its mechanical properties.
  • a PEG-based crosslinking agent disclosed herein is of tunable size.
  • a trifunctional PEG-based crosslinking agent comprises three polymer chains emanating from a central core group, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a tetrafunctional PEG-based crosslinking agent comprises four polymer chains emanating from a central core group with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a pentafunctional PEG-based crosslinking agent comprises five polymer chains emanating from a central core group, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a hexafunctional PEG-based crosslinking agent comprises six polymer chains emanating from a central core group, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a heptafunctional PEG-based crosslinking agent comprises seven polymer chains emanating from a central core group, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • an octafunctional PEG-based crosslinking agent comprises eight polymer chains emanating from a central core group, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a nonafunctional PEG-based crosslinking agent comprises nine polymer chains emanating from a central core group, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a decafunctional PEG-based crosslinking agent comprises ten polymer chains emanating from a central core group, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a core group can be a carbon atom, a generational carbon like a first or second generation carbon, or a dendrite.
  • a trifunctional PEG-based crosslinking agent comprises three polymer chains emanating from a PEG polymer backbone having the structure HO(CH 2 CH 2 0) m H, where m is an integer from 2 to 100, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a tetrafunctional PEG-based crosslinking agent comprises four polymer chains emanating from a PEG polymer backbone having the structure HO(CH 2 CH 2 0) m H, where m is an integer from 2 to 100, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a pentafunctional PEG-based crosslinking agent comprises five polymer chains emanating from a PEG polymer backbone having the structure HO(CH 2 CH 2 0) m H, where m is an integer from 2 to 100, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a hexafunctional PEG-based crosslinking agent comprises six polymer chains emanating from a PEG polymer backbone having the structure HO(CH 2 CH 2 0) m H, where m is an integer from 2 to 100, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a heptafunctional PEG-based crosslinking agent comprises seven polymer chains emanating from a PEG polymer backbone having the structure HO(CH 2 CH 2 0) m H, where m is an integer from 0 to 100, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • an octafunctional PEG-based crosslinking agent comprises eight polymer chains emanating from a PEG polymer backbone having the structure HO(CH 2 CH 2 0) m H, where m is an integer from 2 to 100, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a nonafunctional PEG-based crosslinking agent comprises nine polymer chains emanating from a PEG polymer backbone having the structure HO(CH 2 CH 2 0) m H, where m is an integer from 2 to 100, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a decafunctional PEG-based crosslinking agent comprises ten polymer chains emanating from a PEG polymer backbone having the structure HO(CH 2 CH 2 0) m H, where m is an integer from 2 to 100, with each chain having the structure CH 2 (OCH 2 CH 2 ) n OCH 2 epoxide, where n is an integer from 0 to 60.
  • a bifunctional PEG-based crosslinking agent has a molecular weight of between about 200 Da to about 10,000 Da.
  • a trifunctional PEG-based crosslinking agent has a molecular weight of between about 200 Da to about 10,000 Da.
  • a tetrafunctional PEG-based crosslinking agent has a molecular weight of between about 200 Da to about 10,000 Da.
  • a pentafunctional PEG-based crosslinking agent has a molecular weight of between about 200 Da to about 10,000 Da.
  • a hexafunctional PEG-based crosslinking agent has a molecular weight of between about 200 Da to about 10,000 Da.
  • Matrix polymers such as e.g., polysaccharides polymers like glycosaminoglycan polymers, may be crosslinked with only one type of multifunctional PEG-based crosslinker or with two or more different types of multifunctional PEG-based crosslinkers.
  • glycosaminoglycan polymer strands may be crosslinked solely with a trifunctional PEG-based crosslinker, a tetrafunctional PEG-based crosslinker, a pentafunctional PEG-based crosslinker, a hexafunctional PEG-based crosslinker, a heptafunctional PEG-based crosslinker, an octafunctional PEG-based crosslinker, a nonafunctional PEG-based crosslinker, or a decafunctional PEG-based crosslinker.
  • glycosaminoglycan polymer strands may be crosslinked using a combination of, e.g., trifunctional and tetrafunctional PEG-based crosslinkers, trifunctional and pentafunctional PEG-based crosslinkers, tetrafunctional and pentafunctional PEG-based crosslinkers, tetrafunctional and hexafunctional PEG-based crosslinkers, tetrafunctional and octafunctional PEG-based crosslinkers, pentafunctional and hexafunctional PEG-based crosslinkers, pentafunctional and hepafunctional PEG-based crosslinkers, or pentafunctional and nonafunctional PEG-based crosslinkers.
  • trifunctional and tetrafunctional PEG-based crosslinkers trifunctional and pentafunctional PEG-based crosslinkers
  • tetrafunctional and pentafunctional PEG-based crosslinkers tetrafunctional and pentafunctional PEG-based crosslinkers
  • the mechanical strength of the resulting hydrogel can be tailored to the desired specifications (see, e.g., Examples 5, 6, and 7).
  • Matrix polymers such as e.g., polysaccharides polymers like glycosaminoglycan polymers, may be crosslinked solely with the multifunctional PEG-based crosslinkers disclosed herein or in combination with any other crosslinking agent suitable for making crosslinked hyaluronan.
  • crosslinking agents include dialdehydes and disufides crosslinking agents including, without limitation, divinyl sulfones, diglycidyl ethers, and bis-epoxides.
  • Non-limiting examples of hyaluronan crosslinking agents include divinyl sulfone (DVS), 1 ,4-butanediol diglycidyl ether (BDDE), l,2-bis(2,3-epoxypropoxy)ethylene (EGDGE), 1,2,7,8-diepoxyoctane (DEO), biscarbodiimide (BCDI), adipic dihydrazide (ADH), bis(sulfosuccinimidyl)suberate (BS), hexamethylenediamine (HMD A), l-(2,3-epoxypropyl)-2,3- epoxycyclohexane, or combinations thereof.
  • DVD divinyl sulfone
  • BDDE 1 ,4-butanediol diglycidyl ether
  • EGDGE 1,2,7,8-diepoxyoctane
  • BCDI biscarbodiimide
  • ADH bis(sulfos
  • the mechanical strength and hardness of the final hyaluronan composition may be tuned as desired (see, e.g., Examples 5, 6, and 7).
  • glycosaminoglycan polymers are crosslinked using a combination of PEG-based crosslinkers disclosed herein and BDDE.
  • glycosaminoglycan polymer strands are crosslinked using a combination of PEG- based crosslinkers disclosed herein and EGDGE.
  • glycosaminoglycan polymer strands are crosslinked using a combination of PEG-based crosslinkers disclosed herein and DEO.
  • glycosaminoglycan polymer strands are crosslinked using a combination of PEG-based crosslinkers disclosed herein and DVS.
  • Matrix polymers such as e.g., polysaccharides polymers like glycosaminoglycan polymers, are crosslinked using the PEG-based crosslinking agents disclosed herein using conventional procedures known to a person of ordinary skill.
  • glycosaminoglycan polymers are brought into contact with a PEG-based crosslinker and allowed to react.
  • the glycosaminoglycan polymers may be reacted with more than one PEG-based crosslinker as disclosed herein in either a step-wise fashion, with a lower functionality PEG-based crosslinker being brought into contact first or with a higher functionality PEG-based crosslinker being brought into contact first.
  • glycosaminoglycan polymers may be reacted with a plurality of PEG-based crosslinkers in one step.
  • Matrix polymers such as e.g., polysaccharides polymers like glycosaminoglycan polymers, that may be crosslinked using the PEG-based crosslinking agents and methods disclosed herein.
  • Additional matrix polymers such as e.g., polysaccharides polymers like glycosaminoglycan polymers, that may be crosslinked using the PEG-based crosslinking agents and methods disclosed herein are described in, e.g., Piron and Tholin, Polysaccharide Crosslinking, Hydrogel Preparation, Resulting Polysaccharides(s) and Hydrogel(s), uses Thereof, U.S.
  • Any conventional crosslinking method may be used to crosslink glycosaminoglycan polymers using a multifunctional PEG-based crosslinker disclosed herein alone, with another type of multifunctional PEG-based crosslinker, and/or with conjunction with a non-PEG-based crosslinker.
  • a matrix polymer undergoes a preparation step and then is simply mixed with a crosslinker in order to initiate the crosslinking reaction.
  • a glycosaminoglycan is first hydrated by mixing the polymer with a 0.01-1% sodium hydroxide solution and incubating at ambient temperature for about 1 hour to about 5 hours.
  • an appropriate multifunctional PEG-based crosslinking agent(s) (about 200 Da to about 10,000 Da) is added to the hydrated glycosaminoglycan. If a non-PEG-based crosslinker is also employed, about 20 to about 200 mg of non-PEG-based crosslinker is added as well.
  • the mixture is then mechanically homogenized, and then placed in an about 40 to about 70 C oven for about 1 hour to about 10 hours.
  • the resulting crosslinked hydrogel is neutralized with an equimolar amount of hydrochloric acid and swelled in a physiologically-acceptable solution, such as, e.g., a buffered solution of about pH 5.5 to about pH 8.5.
  • a physiologically-acceptable solution such as, e.g., a buffered solution of about pH 5.5 to about pH 8.5.
  • a crosslinking reaction comprises about 90%> (w/w) glycosaminoglycan polymer and about 10% multifunctional PEG-based crosslinking agent
  • a crosslinking reaction comprises about 89%> (w/w) glycosaminoglycan polymer and about 11%> multifunctional PEG-based crosslinking agent
  • a crosslinking reaction comprises about 88% (w/w) glycosaminoglycan polymer and about 12% multifunctional PEG-based crosslinking agent
  • a crosslinking reaction comprises about 87% (w/w) glycosaminoglycan polymer and about 13% multifunctional PEG-based crosslinking agent
  • a crosslinking reaction comprises about 86%o (w/w) glycosaminoglycan polymer and about 14% multifunctional PEG-based crosslinking agent
  • a crosslinking reaction comprises about 85% (w/w) glycosaminoglycan polymer and about 15% multifunctional PEG-based crosslinking agent
  • a crosslinking reaction comprises
  • a crosslinking reaction comprises about 90% (w/w) glycosaminoglycan polymer and about 10% pentaerythritol tetraglycidyl ether (PEGE) crosslinking agent
  • PEGE pentaerythritol tetraglycidyl ether
  • a crosslinking reaction comprises about 89%> (w/w) glycosaminoglycan polymer and about 11% PEGE crosslinking agent
  • a crosslinking reaction comprises about 88% (w/w) glycosaminoglycan polymer and about 12% PEGE
  • a crosslinking reaction comprises about 87%o (w/w) glycosaminoglycan polymer and about 13% PEGE
  • a crosslinking reaction comprises about 86% (w/w) glycosaminoglycan polymer and about 14% PEGE
  • a crosslinking reaction comprises about 85% (w/w) glycosaminoglycan polymer and about 15% PEGE
  • the composition is crosslinked with between about 10% and about 20% pentaerythritol tetra glycidyl ether (PEGE)/NaHA (w/w), for example, about 13% pentaerythritol tetra glycidyl ether (PEGE)/NaHA (w/w).
  • PEGE pentaerythritol tetra glycidyl ether
  • the hyaluronan polymer has a mean molecular weight of between about 310,000 Da and about 840,000 Da and is crosslinked with PEGE.
  • the initial PEGE crosslinking reaction is about 10% to about 15% (w/w), for example, about 13% PEGE (w/w).
  • the concentration of NaHA in the final composition is about 20 to about 30 mg HA/g (mg/g).
  • glycosammoglycan is synonymous with “GAG” and "mucopolysaccharide” and refers to long unbranched polysaccharides consisting of a repeating disaccharide units.
  • the repeating unit consists of a hexose (six-carbon sugar) or a hexuronic acid, linked to a hexosamine (six-carbon sugar containing nitrogen) and pharmaceutically acceptable salts thereof.
  • GAGs Members of the GAG family vary in the type of hexosamine, hexose or hexuronic acid unit they contain, such as, e.g., glucuronic acid, iduronic acid, galactose, galactosamine, glucosamine) and may also vary in the geometry of the glycosidic linkage. Any glycosammoglycan is useful in the compositions disclosed herein with the proviso that the glycosammoglycan improves a soft tissue condition as disclosed herein. GAGs useful in the compositions and methods disclosed herein are commercially available.
  • Hyaluronan includes anionic, non-sulfated glycosammoglycan polymers comprising disaccharide units, which themselves include D-glucuronic acid and D-N-acetylglucosamine monomers, linked together via alternating ⁇ -1,4 and ⁇ -1,3 glycosidic bonds and pharmaceutically acceptable salts thereof.
  • Hyaluronan can be purified from animal and non-animal sources.
  • Polymers of hyaluronan can range in size from about 5,000 Da to about 20,000,000 Da. Any hyaluronan is useful in the compositions disclosed herein with the proviso that the hyaluronan improves a soft tissue condition as disclosed herein.
  • Non-limiting examples of pharmaceutically acceptable salts of hyaluronan include sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, and combinations thereof.
  • a hydrogel composition comprising crosslinked glycosammoglycan polymers having a degree of crosslinking.
  • degree of crosslinking refers to the percentage of monomeric units of a glycosammoglycan polymer that are bound to a cross-linking agent, such as, e.g., the disaccharide monomer units of hyaluronan.
  • a hydrogel composition comprising crosslinked glycosammoglycan polymers with a 4% degree of crosslinking means that on average there are four crosslinking molecules for every 100 monomeric units. Every other parameter being equal, the greater the degree of crosslinking, the harder a composition comprising crosslinked glycosaminoglycan polymers becomes.
  • a hydrogel composition comprises crosslinked glycosaminoglycan polymers where the degree of crosslinking is between about about 1% and about 40%, for example, between about 2% and about 38%, for example, between about 4% and about 36%), for example, between about 6%> and about 34%, for example, between about 8% and about 32%) for example, between about 10% and about 30% for example, between about 12% and about 28%, for example, between about 14% and about 26% for example, between about 16% and about 24% for example, between about 18% and about 22%, for example, about 20%.
  • At least a portion of the HA in the compositions may be uncrosslinked.
  • the term "uncrosslinked” refers to a lack of intermolecular bonds joining the individual matrix polymer molecules, or monomer chains. As such, an uncrosslinked glycosaminoglycan polymer is not linked to any other glycosaminoglycan polymers by an intermolecular bond.
  • the compositions may comprise uncrosslinked glycosaminoglycan polymers where the uncrosslinked glycosaminoglycan polymers represents, e.g., about 20% or less by weight, about 18% or less by weight, about 15% or less by weight, about 12% or less by weight, about 10% or less by weight, about 9%) or less by weight, about 8% or less by weight, about 7% or less by weight, about 6% or less by weight, about 5% or less by weight, about 4% or less by weight, about 3% or less by weight, about 2% or less by weight, of the total amount of glycosaminoglycan polymers present in the composition.
  • the uncrosslinked glycosaminoglycan polymers represents, e.g., about 20% or less by weight, about 18% or less by weight, about 15% or less by weight, about 12% or less by weight, about 10% or less by weight, about 9%) or less by weight, about 8% or less by weight, about 7% or less by weight, about 6% or less
  • a hydrogel composition comprises uncrosslinked glycosaminoglycan polymers where the uncrosslinked glycosaminoglycan polymers represents, e.g., about 10% to about 20% by weight, about 10% to about 15% by weight, about 5% to about 20% by weight, about 5% to about 15% by weight, about 5% to about 10%) by weight, about 2% to about 20% by weight, about 2% to about 15% by weight, about 2% to about 10% by weight, or about 2% to about 5% by weight, of the total amount of glycosaminoglycan polymers present in the composition.
  • the uncrosslinked glycosaminoglycan polymers represents, e.g., about 10% to about 20% by weight, about 10% to about 15% by weight, about 5% to about 20% by weight, about 5% to about 15% by weight, about 5% to about 10%) by weight, about 2% to about 20% by weight, about 2% to about 15% by weight, about 2% to about 10% by weight, or about 2% to about 5% by weight, of the total amount
  • the compositions are made of substantially entirely low molecular weight hyaluronan polymers prior to the crosslinking, that is at least about 90% or more, by weight, of the hyaluronic acid in the compositions is what is referred to as low molecular weight hyaluronic acid.
  • low molecular weight hyaluronan polymer or “low molecular weight hyaluronan” refers to a hyaluronan polymer that has a molecular weight of less than 1,000,000 Da, more specifically, about 900,000 Da or less.
  • Such low molecular weight hyaluronan polymers include a hyaluronan polymers of about 200,000 Da, about 300,000 Da, about 400,000 Da, about 500,000 Da, about 600,000 Da, about 700,000 Da, about 800,000 Da, or about 900,000 Da.
  • all of the hyaluronic acid in the compositions that is 100% of the hyaluronic acid in the compositions, comprises such low molecular weight hyaluronic acid having a mean molecular weight of between about 300,000 Da and about 900,000 Da.
  • the compositions comprise at least some high molecular weight hyaluronan polymers.
  • high molecular weight hyaluronan polymer or “high molecular weight hyaluronan” refers to a hyaluronan polymer that has a molecular weight of 1,000,000 Da or greater.
  • Non-limiting examples of a high molecular weight hyaluronan polymer include a hyaluronan polymer of about 1,500,000 Da, about 2,000,000 Da, about 2,500,000 Da, about 3,000,000 Da, about 3,500,000 Da, about 4,000,000 Da, about 4,500,000 Da, or about 5,000,000 Da.
  • the compositions are made by the process of crosslinking the low molecular weight hyaluronic acid with a tetrafunctional PEG crosslinking agent to form a highly viscous gel, then sizing the gel by passing the material through a screen (e.g. mesh size of 25 um, a 43 ⁇ , a 60 um, a 100 um, or 105 ⁇ mesh size) only one time prior to sterilization and packaging in syringes for use.
  • a screen e.g. mesh size of 25 um, a 43 ⁇ , a 60 um, a 100 um, or 105 ⁇ mesh size
  • the bulk gel material is sized by passing the material no more than a single time, through a mesh having a pore size of about 100 ⁇ , prior to sterilization and packaging.
  • the gel may be sized in a more conventional manner used for sizing conventional HA-BDDE based dermal fillers by passing the gel through a mesh a plurality of times.
  • the composition is sized by passing the material through a 25 ⁇ , a 43 ⁇ , a 60 ⁇ , or a 105 ⁇ , mesh screen twice, three times, four times, five times, six times, seven times, eight times, nine times, or ten times.
  • anesthetic agent is preferably a local anesthetic agent, i.e., an anesthetic agent that causes a reversible local anesthesia and a loss of nociception, such as, e.g., aminoamide local anesthetics and aminoester local anesthetics.
  • the amount of an anesthetic agent included in a hydrogel composition disclosed herein is an amount effective to mitigate pain experienced by an individual upon administration of the composition.
  • an anesthetic agent included in a hydrogel composition disclosed herein is between about 0.1% (w/w) to about 5% (w/w) by weight of the total composition.
  • anesthetic agents include ambucaine, amolanone, amylocaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine, cocaethylene, ***e, cyclomethycaine, dibucaine, dimethysoquin, dimethocaine, diperodon, dycyclonine, ecgonidine, ecgonine, ethyl chloride, etidocaine, beta-eucaine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxytetracaine, isobutyl p-
  • the composition includes a lidocaine, for example, lidocaine chlorhydrate at an effective concentration so as to reduce pain upon injection.
  • the composition may include lidocaine at a concentration of between about 0.27 % to about 0.33% w/w, or more specifically about 0.30%> w/w.
  • compositions as disclosed herein are viscoelastic in that the composition has an elastic component (solid-like such as, e.g., crosslinked glycosaminoglycan polymers) and a viscous component (liquid-like such as, e.g., uncrosslinked glycosaminoglycan polymers or a carrier phase) when a force is applied (stress, deformation).
  • an elastic component solid-like such as, e.g., crosslinked glycosaminoglycan polymers
  • a viscous component liquid-like such as, e.g., uncrosslinked glycosaminoglycan polymers or a carrier phase
  • the rheo logical attribute that described this property is the complex modulus (G*), which defines a composition's total resistance to deformation.
  • the complex modulus can be defined as the sum of the elastic modulus (G') and the viscous modulus (G").
  • G' elastic modulus
  • G" viscous modulus
  • Viscous modulus is also known as the loss modulus because it describes the energy that is lost as viscous dissipation.
  • a tan ⁇ is obtained from the dynamic modulus at a frequency of 0.628 rad/s.
  • a lower tan ⁇ corresponds to a stiffer, harder, or more elastic composition.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a complex modulus.
  • a hydrogel composition exhibits a complex modulus of, e.g., about 25 Pa, about 50 Pa, about 75 Pa, about 100 Pa, about 125 Pa, about 150 Pa, about 175 Pa, about 200 Pa, about 250 Pa, about 300 Pa, about 350 Pa, about 400 Pa, about 450 Pa, about 500 Pa, about 550 Pa, about 600 Pa, about 650 Pa, about 700 Pa, about 750 Pa, or about 800 Pa.
  • a hydrogel composition exhibits a complex modulus of, e.g.
  • a hydrogel composition exhibits a complex modulus of, e.g., about 25 Pa to about 150 Pa, about 25 Pa to about 300 Pa, about 25 Pa to about 500 Pa, about 25 Pa to about 800 Pa, about 125 Pa to about 300 Pa, about 125 Pa to about 500 Pa, or about 125 Pa to about 800 Pa.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits an elastic modulus.
  • a hydrogel composition exhibits an elastic modulus of, e.g., about 25 Pa, about 50 Pa, about 75 Pa, about 100 Pa, about 125 Pa, about 150 Pa, about 175 Pa, about 200 Pa, about 250 Pa, about 300 Pa, about 350 Pa, about 400 Pa, about 450 Pa, about 500 Pa, about 550 Pa, about 600 Pa, about 650 Pa, about 700 Pa, about 750 Pa, about 800 Pa, about 850 Pa, about 900 Pa, about 950 Pa, about 1,000 Pa, about 1,200 Pa, about 1,300 Pa, about 1,400 Pa, about 1,500 Pa, about 1,600 Pa, about 1700 Pa, about 1800 Pa, about 1900 Pa, about 2,000 Pa, about 2,100 Pa, about 2,200 Pa, about 2,300 Pa, about 2,400 Pa, or about 2,500 Pa.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a viscous modulus.
  • a hydrogel composition exhibits a viscous modulus of, e.g. , about 10 Pa to about 700 Pa, for example, about 20 Pa, about 30 Pa, about 40 Pa, about 50 Pa, about 60 Pa, about 70 Pa, about 80 Pa, about 90 Pa, about 100 Pa, about 150 Pa, about 200 Pa, about 250 Pa, about 300 Pa, about 350 Pa, about 400 Pa, about 450 Pa, about 500 Pa, about 550 Pa, about 600 Pa, about 650 Pa, or about 700 Pa.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a hardness.
  • a hydrogel composition exhibits a hardness of, e.g., about 25 Pa, about 50 Pa, about 75 Pa, about 100 Pa, about 125 Pa, about 150 Pa, about 175 Pa, about 200 Pa, about 250 Pa, about 300 Pa, about 350 Pa, about 400 Pa, about 450 Pa, about 500 Pa, about 550 Pa, about 600 Pa, about 650 Pa, about 700 Pa, about 750 Pa, or about 800 Pa.
  • a hydrogel composition exhibits a hardness of, e.g., at least 25 Pa, at least 50 Pa, at least 75 Pa, at least 100 Pa, at least 125 Pa, at least 150 Pa, at least 175 Pa, at least 200 Pa, at least 250 Pa, at least 300 Pa, at least 350 Pa, at least 400 Pa, at least 450 Pa, at least 500 Pa, at least 550 Pa, at least 600 Pa, at least 650 Pa, at least 700 Pa, at least 750 Pa, or at least 800 Pa.
  • a hydrogel composition exhibits a hardness of, e.g. , about 100 Pa to about 150 Pa, about 100 Pa to about 300 Pa, about 100 Pa to about 500 Pa, about 100 Pa to about 800 Pa, about 125 Pa to about 300 Pa, about 125 Pa to about 500 Pa, or about 125 Pa to about 800 Pa.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a tan ⁇ .
  • a hydrogel composition exhibits a tan ⁇ of, e.g., about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about
  • a hydrogel composition exhibits a tan ⁇ of, e.g., at most 0.1, at most 0.2, at most 0.3, at most 0.4, at most 0.5, at most 0.6, at most 0.7, at most 0.8, at most 0.9, at most 1.0, at most 1.1 , at most 1.2, at most 1.3, at most
  • a hydrogel composition exhibits a tan ⁇ of, e.g., about 0.1 to about 0.3, about 0.3 to about 0.5, about 0.5 to about 0.8, about 1.1 to about 1.4, about 1.4 to about 1.7, about 0.3 to about 0.6, about 0.1 to about 0.5, about 0.5 to about 0.9, about 0.1 to about 0.6, about 0.1 to about 1.0, about 0.5 to about 1.5, about 1.0 to about 2.0, or about 1.5 to about 2.5.
  • Viscosity is resistance of a fluid to shear or flow caused by either shear stress or tensile stress. Viscosity describes a fluid's internal resistance to flow caused by intermolecular friction exerted when layers of fluids attempt to slide by one another and may be thought of as a measure of fluid friction. The less viscous the fluid, the greater its ease of movement (fluidity).
  • Viscosity can be defined in two ways; dynamic viscosity ( ⁇ , although ⁇ is sometimes used) or kinematic viscosity (v).
  • Dynamic viscosity also known as absolute or complex viscosity, is the tangential force per unit area required to move one horizontal plane with respect to the other at unit velocity when maintained a unit distance apart by the fluid.
  • the SI physical unit of dynamic viscosity is the Pascal-second (Pa-s), which is identical to N-m-2-s.
  • Dynamic viscosity symbolize by is also used, is measured with various types of rheometers, devices used to measure the way in which a liquid, suspension or slurry flows in response to applied forces.
  • the viscosity of a material is highly temperature dependent and for either dynamic or kinematic viscosity to be meaningful, the reference temperature must be quoted.
  • a dynamic viscosity is measured at 1 Pa with a cone/plane geometry 2°/40cm and a temperature of 20 °C.
  • Examples of the dynamic viscosity of various fluids at 20 °C is as follows: water is about 1.0 x 10 "3 Pa-s, blood is about 3-4 x 10 "3 Pa-s, vegetable oil is about 60-85 x 10 "3 Pa-s, motor oil SE 30 is about 0.2 Pa-s, glycerin is about 1.4 Pa-s, maple syrup is about 2-3 Pa-s, honey is about 10 Pa-s, chocolate syrup is about 10-25 Pa-s, peanut butter is about 150-250 Pa-s, lard is about 1,000 Pa-s, vegetable shortening is about 1,200 Pa-s, and tar is about 30,000 Pa-s.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a dynamic viscosity of, e.g., about 10 Pa-s, about 20 Pa-s, about 30 Pa-s, about 40 Pa-s, about 50 Pa-s, about 60 Pa-s, about 70 Pa-s, about 80 Pa-s, about 90 Pa-s, about 100 Pa-s, about 125 Pa-s, about 150 Pa-s, about 175 Pa-s, about 200 Pa-s, about 225 Pa-s, about 250 Pa-s, about 275 Pa-s, about 300 Pa-s, about 400 Pa-s, about 500 Pa-s, about 600 Pa-s, about 700 Pa-s, about 750 Pa-s, about 800 Pa-s, about 900 Pa-s, about 1,000 Pa-s, about 1,100 Pa-s, or about 1 ,200 Pa-s.
  • a dynamic viscosity e.g., about 10 Pa-s, about 20 Pa-s, about 30 Pa-s, about 40
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a dynamic viscosity of, e.g., at most 10 Pa-s, at most 20 Pa-s, at most 30 Pa-s, at most 40 Pa-s, at most 50 Pa-s, at most 60 Pa-s, at most 70 Pa-s, at most 80 Pa-s, at most 90 Pa-s, at most 100 Pa-s, at most 125 Pa-s, at most 150 Pa-s, at most 175 Pa-s, at most 200 Pa-s, at most 225 Pa-s, at most 250 Pa-s, at most 275 Pa-s, at most 300 Pa-s, at most 400 Pa-s, at most 500 Pa-s, at most 600 Pa-s, at most 700 Pa-s, at most 750 Pa-s, at most 800 Pa-s, at most 900 Pa-s, or at most 1000 Pa-s.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a dynamic viscosity of, e.g., about 10 Pa-s to about 100 Pa-s, about 10 Pa-s to about 150 Pa-s, about 10 Pa-s to about 250 Pa-s, about 50 Pa-s to about 100 Pa-s, about 50 Pa-s to about 150 Pa-s, about 50 Pa-s to about 250 Pa-s, about 100 Pa-s to about 500 Pa-s, about 100 Pa-s to about 750 Pa-s, about 100 Pa-s to about 1,000 Pa-s, about 100 Pa-s to about 1,200 Pa-s, about 300 Pa-s to about 500 Pa-s, about 300 Pa-s to about 750 Pa-s, about 300 Pa-s to about 1,000 Pa-s, or about 300 Pa-s to about 1,200 Pa-s.
  • a dynamic viscosity e.g., about 10 Pa-s to about 100 Pa-s, about 10 Pa-s to about 150 Pa-s, about 10
  • aspects of the present specification provide, in part, a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein that is injectable.
  • injectable refers to a material having the properties necessary to administer the composition into a soft tissue part, area and/or region of an individual using an injection device with a fine needle.
  • fine needle refers to a needle that is 22 gauge or smaller.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein is injectable through a fine needle.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein is injectable through a needle of, e.g., about 22 gauge, about 27 gauge, about 30 gauge, or about 32 gauge.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein is injectable through a needle of, e.g., 22 gauge or smaller, 27 gauge or smaller, 30 gauge or smaller, or 32 gauge or smaller.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein is injectable through a needle of, e.g., about 22 gauge to about 32 gauge, about 22 gauge to about 27 gauge, or about 27 gauge to about 32 gauge.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein can be injected through a 27 gauge needle with an extrusion force of about 60 N, about 55 N, about 50 N, about 45 N, about 40 N, about 35 N, about 30 N, about 25 N, about 20 N, about 15 N, or about 10 N.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein can be injected through a 27 gauge needle with an extrusion force of about 60 N or less, about 55 N or less, about 50 N or less, about 45 N or less, about 40 N or less, about 35 N or less, about 30 N or less, about 25 N or less, about 20 N or less, about 15 N or less, about 10 N or less, or about 5 N or less.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein can be injected through a 32 gauge needle with an extrusion force of about 60 N, about 55 N, about 50 N, about 45 N, about 40 N, about 35 N, about 30 N, about 25 N, about 20 N, about 15 N, or about 10 N.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein can be injected through a 32 gauge needle with an extrusion force of about 60 N or less, about 55 N or less, about 50 N or less, about 45 N or less, about 40 N or less, about 35 N or less, about 30 N or less, about 25 N or less, about 20 N or less, about 15 N or less, about 10 N or less, or about 5 N or less.
  • aspects of the present specification provide, in part, a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein that exhibits cohesivity.
  • Cohesivity also referred to as cohesion cohesive attraction, cohesive force, or compression force is a physical property of a material, caused by the intermolecular attraction between like- molecules within the material that acts to unite the molecules. Cohesivity is expressed in terms of grams-force (gmf).
  • a composition should be sufficiently cohesive as to remain localized to a site of administration. Additionally, in certain applications, a sufficient cohesiveness is important for a composition to retain its shape, and thus functionality, in the event of mechanical load cycling.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits cohesivity, on par with water.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits sufficient cohesivity to remain localized to a site of administration.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits sufficient cohesivity to retain its shape.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits sufficient cohesivity to retain its shape and functionality.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein has a cohesivity of, e.g., about 10 gmf, about 20 gmf, about 30 gmf, about 40 gmf, about 50 gmf, about 60 gmf, about 70 gmf, about 80 gmf, about 90 gmf, about 100 gmf, about 150 gmf, or about 200 gmf.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein has a cohesivity of, e.g., at least 10 gmf, at least 20 gmf, at least 30 gmf, at least 40 gmf, at least 50 gmf, at least 60 gmf, at least 70 gmf, at least 80 gmf, at least 90 gmf, at least 100 gmf, at least 150 gmf, or at least 200 gmf.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein has a cohesivity of, e.g., at most 10 gmf, at most 20 gmf, at most 30 gmf, at most 40 gmf, at most 50 gmf, at most 60 gmf, at most 70 gmf, at most 80 gmf, at most 90 gmf, at most 100 gmf, at most 150 gmf, or at most 200 gmf.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein has a cohesivity of, e.g., about 50 gmf to about 150 gmf, about 60 gmf to about 140 gmf, about 70 gmf to about 130 gmf, about 80 gmf to about 120 gmf, or about 90 gmf to about 110 gmf.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein has a cohesivity of, e.g., about 10 gmf to about 50 gmf, about 25 gmf to about 75 gmf, about 50 gmf to about 150 gmf, about 100 gmf to about 200 gmf, about 100 gmf to about 300 gmf, about 100 gmf to about 400 gmf, about 100 gmf to about 500 gmf, about 200 gmf to about 300 gmf, about 200 gmf to about 400 gmf, about 200 gmf to about 500 gmf, about 200 gmf to about 600 gmf, about 200 gmf to about 700 gmf, about 300 gmf to about 400 gmf, about 300 gmf to about 500 gmf, about 300 gmf to about 400 gmf, about 300 gmf
  • aspects of the present specification provide, in part, a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein that exhibits a physiologically-acceptable osmolarity.
  • osmolality refers to the concentration of osmotically active solutes in solution.
  • a physiologically-acceptable osmolarity refers to an osmolarity in accord with, or characteristic of, the normal functioning of a living organism.
  • administration of a hydrogel composition as disclosed herein exhibits an osmolarity that has substantially no long term or permanent detrimental effect when administered to a mammal.
  • Osmolarity is expressed in terms of osmoles of osmotically active solute per liter of solvent (Osmol/L or Osm/L). Osmolarity is distinct from molarity because it measures moles of osmotically active solute particles rather than moles of solute. The distinction arises because some compounds can dissociate in solution, whereas others cannot.
  • osmolarity of a hydrogel composition disclosed herein can be measured using a conventional method that measures solutions.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a physiologically-acceptable osmolarity.
  • a hydrogel composition exhibits an osmolarity of, e.g., about 100 mOsm/L, about 150 mOsm/L, about 200 mOsm/L, about 250 mOsm/L, about 300 mOsm/L, about 350 mOsm/L, about 400 mOsm/L, about 450 mOsm/L, or about 500 mOsm/L.
  • a hydrogel composition exhibits an osmolarity of, e.g., at least 100 mOsm/L, at least 150 mOsm/L, at least 200 mOsm/L, at least 250 mOsm/L, at least 300 mOsm/L, at least 350 mOsm/L, at least 400 mOsm/L, at least 450 mOsm/L, or at least 500 mOsm/L.
  • a hydrogel composition exhibits an osmolarity of, e.g., at most 100 mOsm/L, at most 150 mOsm/L, at most 200 mOsm/L, at most 250 mOsm/L, at most 300 mOsm/L, at most 350 mOsm/L, at most 400 mOsm/L, at most 450 mOsm/L, or at most 500 mOsm/L.
  • a hydrogel composition exhibits an osmolarity of, e.g., about 100 mOsm/L to about 500 mOsm/L, about 200 mOsm/L to about 500 mOsm/L, about 200 mOsm/L to about 400 mOsm/L, about 300 mOsm/L to about 400 mOsm/L, about 270 mOsm/L to about 390 mOsm/L, about 225 mOsm/L to about 350 mOsm/L, about 250 mOsm/L to about 325 mOsm/L, about 275 mOsm/L to about 300 mOsm/L, or about 285 mOsm/L to about 290 mOsm/L.
  • the compositions exhibit an osmolarity of between about 270 mOsm/L and about 390 mOsm/L. In one embodiment the compositions have an osmolarity of about 300 mOsm/L, more specifically, 308 mOsm/L.
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein that exhibits a physiologically-acceptable osmolality.
  • osmolality refers to the concentration of osmotically active solutes per kilo of solvent in the body.
  • a physiologically-acceptable osmolality refers to an osmolality in accord with, or characteristic of, the normal functioning of a living organism. As such, administration of a hydrogel composition disclosed herein exhibits an osmolality that has substantially no long term or permanent detrimental effect when administered to a mammal.
  • Osmolality is expressed in terms of osmoles of osmotically active solute per kilogram of solvent (osmol/kg or Osm/kg) and is equal to the sum of the molalities of all the solutes present in that solution.
  • the osmolality of a solution can be measured using an osmometer.
  • the most commonly used instrument in modern laboratories is a freezing point depression osmometer. This instruments measure the change in freezing point that occurs in a solution with increasing osmolality (freezing point depression osmometer) or the change in vapor pressure that occurs in a solution with increasing osmolality (vapor pressure depression osmometer).
  • a hydrogel composition comprising crosslinked glycosaminoglycan polymers as disclosed herein exhibits a physiologically-acceptable osmolality.
  • a hydrogel composition exhibits an osmolality of, e.g., about 100 mOsm/kg, about 150 mOsm/kg, about 200 mOsm/kg, about 250 mOsm/kg, about 300 mOsm/kg, about 350 mOsm/kg, about 400 mOsm/kg, about 450 mOsm/kg, or about 500 mOsm/kg.
  • a hydrogel composition exhibits an osmolality of, e.g., at least 100 mOsm/kg, at least 150 mOsm/kg, at least 200 mOsm/kg, at least 250 mOsm/kg, at least 300 mOsm/kg, at least 350 mOsm/kg, at least 400 mOsm/kg, at least 450 mOsm/kg, or at least 500 mOsm/kg.
  • a hydrogel composition exhibits an osmolality of, e.g., at most 100 mOsm/kg, at most 150 mOsm/kg, at most 200 mOsm/kg, at most 250 mOsm/kg, at most 300 mOsm/kg, at most 350 mOsm/kg, at most 400 mOsm/kg, at most 450 mOsm/kg, or at most 500 mOsm/kg.
  • a hydrogel composition exhibits an osmolality of, e.g., about 100 mOsm/kg to about 500 mOsm/kg, about 200 mOsm/kg to about 500 mOsm/kg, about 200 mOsm/kg to about 400 mOsm/kg, about 300 mOsm/kg to about 400 mOsm/kg, about 270 mOsm/kg to about 390 mOsm/kg, about 225 mOsm/kg to about 350 mOsm/kg, about 250 mOsm/kg to about 325 mOsm/kg, about 275 mOsm/kg to about 300 mOsm/kg, or about 285 mOsm/kg to about 290 mOsm/kg.
  • This example illustrates how to make a multifunctional PEG-based crosslinking agent useful in the present injectable devices, from a base polyalcohol.
  • a multifunctional PEG-based crosslinking agent such as disclosed elsewhere herein can be synthesized using a general scheme below.
  • a base polyalcohol of about 200 Da to about 10,000 Da, and having the desired length and branching is initially reacted with sodium hydride or any other reagent that can deprotonate the hydroxyl groups and then with epichlorohydrin or any other appropriate epoxide group(s).
  • a 4-arm base alcohol is shown; where n may be an integer of 0 to 60.
  • n may be an integer of 0 to 60.
  • the general chemical schematic is illustrated with a 4-arm base polyalchohol, a similar synthesis scheme is employed to produce other multifunctional PEG-based crosslinking agents by simply using the appropriate base polyalcohol.
  • a bifunctional PEG-based crosslinker For example, to synthesize a bifunctional PEG-based crosslinker, a 2-arm base polyalcohol is used; to synthesis a trifunctional PEG-based crosslinker, a 3 -arm base polyalcohol is used; to synthesis a pentafunctional PEG-based crosslinker, a 5 -arm base polyalcohol is used; to synthesis a hexafunctional PEG-based crosslinker, a 6-arm base polyalcohol is used; to synthesis a heptafunctional PEG-based crosslinker, a 7-arm base polyalcohol is used; to synthesis an octafunctional PEG-based crosslinker, a8-arm base polyalcohol is used; to synthesis a nonafunctional PEG-based crosslinker, a 9-arm base polyalcohol is used; to synthesis a decafunctional PEG-based crosslinker, a 10-arm base polyalcohol is used; etc.
  • This example illustrates how to crosslink glycosaminoglycan polymers using a multifunctional PEG-based crosslinking agent as disclosed herein.
  • the mixture was then mechanically homogenized, and then placed in an about 50 C oven for about 90 minutes.
  • the resulting crosslinked hydrogel is neutralized with an equimolar amount of hydrochloric acid and swelled in a phosphate buffer (pH 7.4).
  • the resulting hydrogel comprising crosslinked hyaluronan polymers was processed once through a 60 ⁇ mesh and dialyzed for one week using a 20 kDa MWCO bag. The dialyzed hydrogel was then transferred to 0.8 mL syringe and flash sterilized at 128 C.
  • a hydrogel composition as disclosed herein was alternatively produced as described above, except that after hydration, about 56 mg (14% w/w) of a tetrafunctional PEG-based crosslinking agent of Example 1 (about 360 Da) was added to the hydrated sodium hyaluronate.
  • the resulting crosslinked hydrogel was neutralized in a solution made of HC1 lN/Phosphate Buffer and swollen (less than 24H) to reach a NaHA concentration of 30mg/g.
  • the resulting hydrogel comprising crosslinked hyaluronan polymers was processed once through a 100 ⁇ mesh filter and dialyzed for about 30-50 hours against a phosphate buffer to reach a concentration of 25 mg/g in NaHA and to remove residual crosslinker. An amount of lidocaine hydrochloride was added to the hydrogel to reach a lidocaine concentration of 0.3% w/w. [00082] The dialyzed hydrogel was then transferred to 0.8 mL COC (cyclo olefin copolymer) syringes and steam sterilized.
  • COC cyclo olefin copolymer
  • compositions are 100% low molecular weight hyaluronic acid (Na-HA) crosslinked with 13% of pentaerythritol tetra glycidyl ether (PEGE)/NaHA (w/w), formulated to a concentration of about 25 mg/g with 0.3% lidocaine hydrochloride (w/w) in a phosphate buffer.
  • PEGE pentaerythritol tetra glycidyl ether
  • lidocaine hydrochloride w/w
  • Procedure Measurements were performed at a constant temperature of 25.0 ⁇ 0.1 °C with a 40mm cone with an angle of 2°. Oscillatory shear tests were performed over a range of frequencies from 0.05Hz to 10Hz, using a constant strain of 8.10 "3 .
  • Instrument Rheometer RS600 (G85), RS6000 (G156) and Mars 3 (G163).
  • G' elastic modulus
  • G" viscous modulus
  • G' was consistently higher than G" for STAR-HA, indicating that the elastic properties of the materials, dominate the viscous properties. There was no crossover point seen in the range of frequencies studied. Results, indicated in Table 1, show the dominance of elastic properties with G'>G" (and consequently tan5 ⁇ 1) for all the range of frequencies studied. Average values of 2308 ⁇ 131Pa and 376 ⁇ 16Pa, for G' and G" respectively, were found at 1 Hz for the compositions of the invention.
  • Injectable devices of the invention used to correct a recessed or retruded chin
  • an injectable device in accordance with the invention comprising an HA-based formulation or composition, for facial augmentation and contouring, is administered by injection through a 25 gauge cannula, (other suitable gauges are useful as well, for example, 22-28 gauge cannulas or needles) supraperiostally, into a chin of a 26 year old male patient suffering from a retruded chin.
  • a 25 gauge cannula other suitable gauges are useful as well, for example, 22-28 gauge cannulas or needles
  • the composition comprises 100% low molecular weight hyaluronic acid (Na-HA) crosslinked with 12% pentaerythritol terra glycidyl ether (PEGE)/NaHA (w/w), formulated to a concentration of about 27 mg/g with 0.3% lidocaine hydrochloride (w/w) in a phosphate buffer.
  • PEGE pentaerythritol terra glycidyl ether
  • w/w w/w
  • the physician carefully injects the composition in a manner so as to provide lift and desirable shape to the chin. 12 months after the procedure, the patient is still satisfied with the results and his chin remains "strong" and appears more masculine. 18 months after the procedure, there is no visible reduction of his chin and he remains satisfied with the results.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un dispositif injectable utile pour un modelage facial et une correction de traits faciaux, par exemple, pour une augmentation du menton chez un patient, ledit dispositif étant constitué d'une composition comprenant un acide hyaluronique réticulé à l'aide d'un agent de réticulation à base de polyéthylèneglycol multifonctionnel (PEG).
PCT/US2013/063507 2012-10-05 2013-10-04 Dispositif injectable et méthode de modelage, d'augmentation ou de correction de traits faciaux tels que du menton WO2014055895A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261710470P 2012-10-05 2012-10-05
US61/710,470 2012-10-05

Publications (1)

Publication Number Publication Date
WO2014055895A1 true WO2014055895A1 (fr) 2014-04-10

Family

ID=49486666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/063507 WO2014055895A1 (fr) 2012-10-05 2013-10-04 Dispositif injectable et méthode de modelage, d'augmentation ou de correction de traits faciaux tels que du menton

Country Status (1)

Country Link
WO (1) WO2014055895A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370498B2 (en) 2005-07-14 2016-06-21 Neothetics, Inc. Methods of using lipolytic formulations for regional adipose tissue treatment
US9452132B2 (en) 2009-05-27 2016-09-27 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
WO2019155391A1 (fr) * 2018-02-06 2019-08-15 Regen Lab Sa Acides hyaluroniques réticulés et combinaisons avec prp/bmc
CN110573190A (zh) * 2017-02-28 2019-12-13 Cg生物技术有限公司 皮肤注入用组合物
CN110573189A (zh) * 2017-02-28 2019-12-13 Cg生物技术有限公司 皮肤注入用组合物
CN110621355A (zh) * 2017-02-28 2019-12-27 Cg生物技术有限公司 皮肤注入用组合物
EP3645063A4 (fr) * 2017-06-26 2021-04-14 Evolved by Nature, Inc. Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés d'utilisation
US11660372B2 (en) 2017-06-26 2023-05-30 Evolved By Nature, Inc. Silk-hyaluronic acid based tissue fillers and methods of using the same

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148995A1 (en) 2000-07-19 2003-08-07 Estelle Piron Polysaccharide crosslinking, hydrogel preparation, resulting polysaccharide(s) and hydrogel(s), uses thereof
WO2004073759A1 (fr) 2003-02-19 2004-09-02 Aventis Pharmaceuticals Holdings Inc. Composition et methode pour augmenter le tissu mou intradermique
US20060194758A1 (en) 2003-04-10 2006-08-31 Pierre Lebreton Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and dydrogels thus obtained
US20080089918A1 (en) 2004-11-30 2008-04-17 Comeal Industrie Viscoelastic Solutions Containing Sodium Hyaluronate And Hydroxypropyl Methyl Cellulose, Preparation And Uses
US20090014333A1 (en) 2007-07-09 2009-01-15 The Curators Of The University Of Missouri Agarose nano-platinum composite
WO2009018076A1 (fr) * 2007-07-30 2009-02-05 Allergan, Inc. Compositions d'acide hyaluronique réticulées ajustables
US20100004198A1 (en) 2007-11-30 2010-01-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20100028438A1 (en) 2008-08-04 2010-02-04 Lebreton Pierre F Hyaluronic Acid-Based Gels Including Lidocaine
US20100098764A1 (en) 2007-11-30 2010-04-22 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US20120071437A1 (en) * 2007-07-30 2012-03-22 Allergan, Inc. Tunable crosslinked polysaccharide compositions

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148995A1 (en) 2000-07-19 2003-08-07 Estelle Piron Polysaccharide crosslinking, hydrogel preparation, resulting polysaccharide(s) and hydrogel(s), uses thereof
WO2004073759A1 (fr) 2003-02-19 2004-09-02 Aventis Pharmaceuticals Holdings Inc. Composition et methode pour augmenter le tissu mou intradermique
US20060194758A1 (en) 2003-04-10 2006-08-31 Pierre Lebreton Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and dydrogels thus obtained
US20080089918A1 (en) 2004-11-30 2008-04-17 Comeal Industrie Viscoelastic Solutions Containing Sodium Hyaluronate And Hydroxypropyl Methyl Cellulose, Preparation And Uses
US20090014333A1 (en) 2007-07-09 2009-01-15 The Curators Of The University Of Missouri Agarose nano-platinum composite
WO2009018076A1 (fr) * 2007-07-30 2009-02-05 Allergan, Inc. Compositions d'acide hyaluronique réticulées ajustables
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US20120071437A1 (en) * 2007-07-30 2012-03-22 Allergan, Inc. Tunable crosslinked polysaccharide compositions
US20100004198A1 (en) 2007-11-30 2010-01-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20100098764A1 (en) 2007-11-30 2010-04-22 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20100028438A1 (en) 2008-08-04 2010-02-04 Lebreton Pierre F Hyaluronic Acid-Based Gels Including Lidocaine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FALCONE ET AL.: "Temporary Polysaccharide Dermal Fillers: A Model for Persistence Based on Physical Properties", DERMATOL SURG., vol. 35, no. 8, 2009, pages 1238 - 1243

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370498B2 (en) 2005-07-14 2016-06-21 Neothetics, Inc. Methods of using lipolytic formulations for regional adipose tissue treatment
US9452147B2 (en) 2005-07-14 2016-09-27 Neothetics, Inc. Lipolytic methods
US9707192B2 (en) 2005-07-14 2017-07-18 Neothetics, Inc. Lipolytic methods
US9452132B2 (en) 2009-05-27 2016-09-27 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CN110573189A (zh) * 2017-02-28 2019-12-13 Cg生物技术有限公司 皮肤注入用组合物
CN110573190A (zh) * 2017-02-28 2019-12-13 Cg生物技术有限公司 皮肤注入用组合物
CN110621355A (zh) * 2017-02-28 2019-12-27 Cg生物技术有限公司 皮肤注入用组合物
CN110621355B (zh) * 2017-02-28 2022-01-21 Cg生物技术有限公司 皮肤注入用组合物
CN110573190B (zh) * 2017-02-28 2022-01-25 Cg生物技术有限公司 皮肤注入用组合物
CN110573189B (zh) * 2017-02-28 2022-01-25 Cg生物技术有限公司 皮肤注入用组合物
US11660372B2 (en) 2017-06-26 2023-05-30 Evolved By Nature, Inc. Silk-hyaluronic acid based tissue fillers and methods of using the same
IL271692B2 (en) * 2017-06-26 2023-06-01 Evolved By Nature Inc Tissue fillers based on hyaluronic acid and silk and methods of using them
EP3645063A4 (fr) * 2017-06-26 2021-04-14 Evolved by Nature, Inc. Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés d'utilisation
EP4169539A1 (fr) * 2017-06-26 2023-04-26 Evolved by Nature, Inc. Charges de tissu à base de soie-acide hyaluronique et leurs procédés d'utilisation
WO2019155391A1 (fr) * 2018-02-06 2019-08-15 Regen Lab Sa Acides hyaluroniques réticulés et combinaisons avec prp/bmc
CN112118849A (zh) * 2018-02-06 2020-12-22 瑞珍实验室 交联透明质酸及与prp/bmc的组合

Similar Documents

Publication Publication Date Title
JP6749993B2 (ja) 抗酸化物質を含む皮膚充填剤組成物
CA3000588C (fr) Compositions de polysaccharide reticulable sur site et leurs utilisations
WO2014055895A1 (fr) Dispositif injectable et méthode de modelage, d'augmentation ou de correction de traits faciaux tels que du menton
KR101672562B1 (ko) 마취제를 포함하는 히알루론산-기반 젤
US20120071437A1 (en) Tunable crosslinked polysaccharide compositions
US20110077737A1 (en) Tunably Crosslinked Polysaccharide Compositions
DK2637710T3 (en) HYALURONIC ACID BASED FORMULATIONS
AU2018228300B2 (en) Composition For Dermal Injection
AU2018228299B2 (en) Composition For Dermal Injection
AU2018228301B2 (en) Composition For Dermal Injection
US20140039062A1 (en) Injectable device and method for sculpting, augmenting or correcting facial features such as the chin
TW202005656A (zh) 同時具有高度黏彈性和內聚性之玻尿酸填料
EP3316921B1 (fr) Procédé de production d'acide hyaluronique réticulé
WO2023275278A1 (fr) Charges dermiques d'acide hyaluronique réticulées avec de l'éther diglycidique de glycol polyéthylénique, leur procédé de fabrication et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13783141

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13783141

Country of ref document: EP

Kind code of ref document: A1